STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
Tag
Biotech
Live stream
RIVO news Listen to this section's headlines in an AI voice
Now:
Press play to start the stream
This browser does not support voice playback. Try Chrome, Edge or Safari.
Biotech
STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.
Biotech
STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
Here is some of what you may have missed from the world's largest cancer research meeting.
Biotech
STAT+: A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
Biotech
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.
Biotech
STAT+: A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
Biotech
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
Biotech
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Biotech
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
Biotech
STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
Biotech
STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
Biotech
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Biotech
STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…
Biotech
STAT+: Allogene CEO David Chang stepping down
Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout
Biotech
STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk
Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the institutions that support these advances, from regulators, to investors, and even public…
Biotech
STAT+: Ahead of ASCO, all eyes on pancreatic cancer
Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout
Adam's Biotech Scorecard
STAT+: An ASCO preview: What to watch for at cancer research’s big meeting
Here's what to watch for at ASCO, cancer research's big meeting, in Chicago.
Biotech
STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
The business of living forever, Chan Zuckerberg Biohub's AI protein model, and other biotech news from The Readout
![Ambitious Belgian biotech goes shopping in US ‘built to be bought’ market [Advocacy Lab]](https://www.rivonews.online/wp-content/uploads/2026/05/GettyImages-168166178-1182x788-1-800x480.jpg)
Belgium
Ambitious Belgian biotech goes shopping in US ‘built to be bought’ market [Advocacy Lab]
Despite Europe’s strong scientific base and growing biotech sector, many companies still turn to US markets for scale and visibility
Biotech
What do early data from Utah’s Doctronic AI pilot show?
In this edition of STAT Health Tech: Early data from a Utah pilot using AI to renew prescriptions, Oura files to go public, and more.
Biotech
STAT+: Five biotech news updates to stay on top of today
Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout
A STAT Examination
STAT+: How Kyle Diamantas defied expectations as he rose to lead the FDA
WASHINGTON — People in the food world didn’t know what to expect when the Trump administration appointed a little-known Florida attorney as the FDA’s top food official in 2025. They…
Biotech
STAT+: An AI biotech CEO sets the record straight on AI drug development hype
CEO of BigHat Biosciences, which designs antibody therapies using machine-learning, on how AI can, and cannot, help in drug development.
Biotech
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
Biotech
STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, it announced Friday.
Biotech
STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the degenerative brain disorder in a randomized trial.
Biotech
STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…
Biotech
STAT+: Immunovant shares surge on arthritis trial data
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout